Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

Background: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in...

Descripción completa

Detalles Bibliográficos
Autores: Garcia-Alfonso, Pilar, Chaves, Manuel, Muñoz, Andrés, Salud Salvia, Maria Antonieta, García-Gonzalez, Maria, Grávalos, Cristina, Massuti, Bartomeu, González-Flores, Encarna, Queralt, Bernardo, López-Ladrón, Amelia, Losa, F., Gómez, Maria Jose, Oltra, Amparo, Aranda, Enrique
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/56603
Acceso en línea:https://doi.org/10.1186/s12885-015-1293-y
http://hdl.handle.net/10459.1/56603
Access Level:acceso abierto
Palabra clave:Irinotecan
Capecitabine
Bevacizumab
Metastatic colorectal cancer
Chemotherapy
id ES_e1aed47cb7d513e2bb3ee079250d8142
oai_identifier_str oai:repositori.udl.cat:10459.1/56603
network_acronym_str ES
network_name_str España
repository_id_str
spelling Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI studyGarcia-Alfonso, PilarChaves, ManuelMuñoz, AndrésSalud Salvia, Maria AntonietaGarcía-Gonzalez, MariaGrávalos, CristinaMassuti, BartomeuGonzález-Flores, EncarnaQueralt, BernardoLópez-Ladrón, AmeliaLosa, F.Gómez, Maria JoseOltra, AmparoAranda, EnriqueIrinotecanCapecitabineBevacizumabMetastatic colorectal cancerChemotherapyBackground: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC. Methods: Patients received intravenous irinotecan 175 mg/m2 on day 1 and oral capecitabine 1000 mg/m2 (800 mg/m2 for patients >65 years of age) twice daily on days 2–8, followed by a 1-week rest, and bevacizumab 5 mg/kg as an intravenous infusion on day 1 every 2 weeks. Results: Seventy-seven patients were included in the intention-to-treat and safety populations. Progression-free survival at 9 months was 61%. The overall response and disease control rates were 51% and 84%, respectively. Median progression-free and overall survival times were 11.9 and 24.8 months, respectively. 48 patients (62%) had at least one grade 3/4 adverse event, the most common being asthenia, diarrhoea and neutropenia. Quality of life varied little over the study period with mean visual analogue scale general health scores ranging from 71 to 76 over cycles 1–11. Conclusion: Our study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with mCRC to be an effective and tolerable regimen. Trial registration: clinicaltrials.gov identifier NCT00875771. Trial registration date: 04/02/2009. Keywords: Irinotecan, Capecitabine, Bevacizumab, Metastatic colorectal cancer, ChemotherapyBioMed Central2015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1186/s12885-015-1293-yhttp://hdl.handle.net/10459.1/56603reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)InglésReproducció del document publicat a https://doi.org/10.1186/s12885-015-1293-yBMC Cancer, 2015, vol.15, núm. 327cc-by, (c) Garcia-Alfonso et al., 2015info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/3.0/es/oai:repositori.udl.cat:10459.1/566032026-06-24T12:42:17Z
dc.title.none.fl_str_mv Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
title Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
spellingShingle Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
Garcia-Alfonso, Pilar
Irinotecan
Capecitabine
Bevacizumab
Metastatic colorectal cancer
Chemotherapy
title_short Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
title_full Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
title_fullStr Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
title_full_unstemmed Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
title_sort Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
dc.creator.none.fl_str_mv Garcia-Alfonso, Pilar
Chaves, Manuel
Muñoz, Andrés
Salud Salvia, Maria Antonieta
García-Gonzalez, Maria
Grávalos, Cristina
Massuti, Bartomeu
González-Flores, Encarna
Queralt, Bernardo
López-Ladrón, Amelia
Losa, F.
Gómez, Maria Jose
Oltra, Amparo
Aranda, Enrique
author Garcia-Alfonso, Pilar
author_facet Garcia-Alfonso, Pilar
Chaves, Manuel
Muñoz, Andrés
Salud Salvia, Maria Antonieta
García-Gonzalez, Maria
Grávalos, Cristina
Massuti, Bartomeu
González-Flores, Encarna
Queralt, Bernardo
López-Ladrón, Amelia
Losa, F.
Gómez, Maria Jose
Oltra, Amparo
Aranda, Enrique
author_role author
author2 Chaves, Manuel
Muñoz, Andrés
Salud Salvia, Maria Antonieta
García-Gonzalez, Maria
Grávalos, Cristina
Massuti, Bartomeu
González-Flores, Encarna
Queralt, Bernardo
López-Ladrón, Amelia
Losa, F.
Gómez, Maria Jose
Oltra, Amparo
Aranda, Enrique
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Irinotecan
Capecitabine
Bevacizumab
Metastatic colorectal cancer
Chemotherapy
topic Irinotecan
Capecitabine
Bevacizumab
Metastatic colorectal cancer
Chemotherapy
description Background: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC. Methods: Patients received intravenous irinotecan 175 mg/m2 on day 1 and oral capecitabine 1000 mg/m2 (800 mg/m2 for patients >65 years of age) twice daily on days 2–8, followed by a 1-week rest, and bevacizumab 5 mg/kg as an intravenous infusion on day 1 every 2 weeks. Results: Seventy-seven patients were included in the intention-to-treat and safety populations. Progression-free survival at 9 months was 61%. The overall response and disease control rates were 51% and 84%, respectively. Median progression-free and overall survival times were 11.9 and 24.8 months, respectively. 48 patients (62%) had at least one grade 3/4 adverse event, the most common being asthenia, diarrhoea and neutropenia. Quality of life varied little over the study period with mean visual analogue scale general health scores ranging from 71 to 76 over cycles 1–11. Conclusion: Our study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with mCRC to be an effective and tolerable regimen. Trial registration: clinicaltrials.gov identifier NCT00875771. Trial registration date: 04/02/2009. Keywords: Irinotecan, Capecitabine, Bevacizumab, Metastatic colorectal cancer, Chemotherapy
publishDate 2015
dc.date.none.fl_str_mv 2015
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1186/s12885-015-1293-y
http://hdl.handle.net/10459.1/56603
url https://doi.org/10.1186/s12885-015-1293-y
http://hdl.handle.net/10459.1/56603
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.1186/s12885-015-1293-y
BMC Cancer, 2015, vol.15, núm. 327
dc.rights.none.fl_str_mv cc-by, (c) Garcia-Alfonso et al., 2015
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/3.0/es/
rights_invalid_str_mv cc-by, (c) Garcia-Alfonso et al., 2015
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:Repositori Obert UdL
instname:Universitat de Lleida (UdL)
instname_str Universitat de Lleida (UdL)
reponame_str Repositori Obert UdL
collection Repositori Obert UdL
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422315182227457
score 15,81155

Similares en LA Referencia